Hemispherx Biopharma, Inc. (NYSE: HEB) announced today the results of a new efficacy study of Ampligen® in a mouse model ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE